Is Sunshine Biopharma Inc. Warrant (SBFMW) overvalued? · rev $34.9M
Sunshine Biopharma Inc. Warrant (SBFMW) common stock listed on NASDAQ.
This page asks whether Sunshine Biopharma Inc. Warrant (SBFMW) looks expensive on cached numbers — not a short thesis.
Latest reported SBFMW revenue for 2024-12-31 was $34.9M. Net income was -$5.1M. Revenue was up 44.7% from 2023-12-31 to 2024-12-31. SBFMW currently screens at market cap $0.
SBFMW currently screens at market cap $0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SBFMW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SBFMW stock page for the full model, not this heading.
Not investment advice.